Literature DB >> 14566476

[Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study-first results].

Jörg Wiltfang1, Gerhard Grabenbauer, Alexandra Bloch-Birkholz, Anna Leher, Friedrich Wilhelm Neukam, Peter Kessler.   

Abstract

BACKGROUND: The treatment of oral cancer has a strong impact on the quality of life. In recent years different therapeutic concepts have been developed, these include preoperative simultaneous "neoadjuvant" radiochemotherapy (RCT) and one-stage surgery with tumor ablation and reconstruction. When considering long-term survival, there is substantial evidence that evidenced modality treatment including neoadjuvant RCT is superior to the primary surgical approach with postoperative radiation. PATIENTS AND METHODS: This longitudinal study prospectively evaluates quality of life in two groups consisting of 53 neoadjuvant and primarily surgically treated patients with oral cancer, using the quality-of-life core questionnaire (QLQ-C30) and the head and neck cancer module (H and N 35) of the European Organization for Research and Treatment of Cancer (EORTC).
RESULTS: Postoperatively both groups showed a marked reduction in quality of life. 1 year later quality of life had equalized between the two groups to such an extent that the quality of life scores had almost reached the preoperative level. Both groups showed specific impairments in the symptom scales. In the neoadjuvant therapy group however, global health and the emotional status were reduced to a greater degree than in the other group.
CONCLUSION: Temporary limitations in quality of life can be expected after tumor treatment of oral cancer as presented here. Neoadjuvant therapy concept is more aggressive and might result in a longer disease-free survival, but the restriction in quality of life is more severe. Primary goal is the eradication of the tumor. Nevertheless preservation or reconstruction of a maximum of function is essential for a high level of quality of life.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566476     DOI: 10.1007/s00066-003-1143-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  6 in total

1.  [Quality of life of patients with squamous cell carcinoma of the oral cavity].

Authors:  J Rabbels; M Wyzisk; M Siessegger; B Klesper; T Reuther; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2005-09

2.  Effect of thymoquinone on head and neck squamous cell carcinoma cells in vitro: Synergism with radiation.

Authors:  Ulana Kotowski; Gregor Heiduschka; Lorenz Kadletz; Tammer Fahim; Rudolf Seemann; Rainer Schmid; Sven Schneider; Andreas Mitterbauer; Dietmar Thurnher
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

3.  [Preoperative radiochemotherapy for advanced oral cavity tumours : the Kiel DOSAK experience regarding curability and quality of life].

Authors:  Jürgen Schultze; Helge Schillmöller; J Camilo Roldán; Jörg Wiltfang; Bernhard Kimmig
Journal:  Mund Kiefer Gesichtschir       Date:  2006-07

4.  Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane.

Authors:  Ulana Kotowski; Gregor Heiduschka; Markus Brunner; Cornelia Czembirek; Christina Eder-Czembirek; Rainer Schmidt; Tammer Fahim; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2011-08-16       Impact factor: 3.621

5.  Neoadjuvant radiotherapy of head and neck carcinoma: an obstacle for plastic reconstruction?

Authors:  Stefan Riml; Franz Böhler; Lorenz Larcher; Alexander de Vries; Wolfgang Elsässer; Peter Kompatscher
Journal:  Wien Klin Wochenschr       Date:  2012-08-01       Impact factor: 1.704

Review 6.  Prognostic factors associated with a restricted mouth opening (trismus) in patients with head and neck cancer: Systematic review.

Authors:  Sarah J van der Geer; Phillip V van Rijn; Jan L N Roodenburg; Pieter U Dijkstra
Journal:  Head Neck       Date:  2020-06-18       Impact factor: 3.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.